Royal Bank of Canada’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History
Bought
Maintained
Sold
Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2025
Q2 | $53K | Sell |
1,558
-2,029
| -57% | -$69K | ﹤0.01% | 5527 |
|
2025
Q1 | $114K | Buy |
3,587
+29
| +0.8% | +$922 | ﹤0.01% | 4781 |
|
2024
Q4 | $139K | Buy |
3,558
+159
| +5% | +$6.21K | ﹤0.01% | 4657 |
|
2024
Q3 | $153K | Sell |
3,399
-1,349
| -28% | -$60.7K | ﹤0.01% | 4584 |
|
2024
Q2 | $199K | Sell |
4,748
-6,317
| -57% | -$265K | ﹤0.01% | 4397 |
|
2024
Q1 | $504K | Buy |
11,065
+7,664
| +225% | +$349K | ﹤0.01% | 3568 |
|
2023
Q4 | $157K | Buy |
3,401
+852
| +33% | +$39.3K | ﹤0.01% | 4764 |
|
2023
Q3 | $103K | Sell |
2,549
-632
| -20% | -$25.5K | ﹤0.01% | 4885 |
|
2023
Q2 | $154K | Buy |
3,181
+982
| +45% | +$47.5K | ﹤0.01% | 4544 |
|
2023
Q1 | $108K | Sell |
2,199
-81
| -4% | -$3.98K | ﹤0.01% | 4745 |
|
2022
Q4 | $115K | Sell |
2,280
-44,658
| -95% | -$2.25M | ﹤0.01% | 4877 |
|
2022
Q3 | $2.36M | Buy |
46,938
+39,346
| +518% | +$1.98M | ﹤0.01% | 2351 |
|
2022
Q2 | $371K | Buy |
7,592
+2,853
| +60% | +$139K | ﹤0.01% | 3892 |
|
2022
Q1 | $285K | Buy |
4,739
+1,323
| +39% | +$79.6K | ﹤0.01% | 4300 |
|
2021
Q4 | $271K | Buy |
3,416
+359
| +12% | +$28.5K | ﹤0.01% | 4526 |
|
2021
Q3 | $271K | Sell |
3,057
-790
| -21% | -$70K | ﹤0.01% | 4393 |
|
2021
Q2 | $383K | Buy |
3,847
+954
| +33% | +$95K | ﹤0.01% | 4052 |
|
2021
Q1 | $260K | Buy |
2,893
+153
| +6% | +$13.8K | ﹤0.01% | 4264 |
|
2020
Q4 | $259K | Sell |
2,740
-198
| -7% | -$18.7K | ﹤0.01% | 4150 |
|
2020
Q3 | $212K | Buy |
2,938
+824
| +39% | +$59.5K | ﹤0.01% | 4048 |
|
2020
Q2 | $148K | Sell |
2,114
-222
| -10% | -$15.5K | ﹤0.01% | 4165 |
|
2020
Q1 | $116K | Buy |
2,336
+8
| +0.3% | +$397 | ﹤0.01% | 4203 |
|
2019
Q4 | $145K | Buy |
2,328
+20
| +0.9% | +$1.25K | ﹤0.01% | 4271 |
|
2019
Q3 | $115K | Buy |
+2,308
| New | +$115K | ﹤0.01% | 4162 |
|